TARA

+ Watchlist + Portfolio

Protara Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.96
52-Week Range: $3.00 – $7.82
Market Cap: $230.47M
P/E (TTM): —
EPS (TTM): -1.36
Dividend Yield: —

Advanced Metrics

Price/Book: 1.19
PEG Ratio: —
Return on Equity: -45.80%
Return on Assets: -28.82%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 10.97
Debt/Equity: 0.02
Total Debt: $2.75M
Free Cash Flow: $-40.49M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $90.73M

TARA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$16.81M	$24.99M	$31.70M	$42.63M
Selling, General & Admin	$20.74M	$18.62M	$17.45M	$21.92M
Operating Expenses	$37.55M	$43.61M	$49.15M	$64.55M
Operating Income	-$37.55M	-$43.61M	-$49.15M	-$64.55M
EBITDA	-$64.57M	-$43.27M	-$48.82M	-$64.19M
Pretax Income	-$65.95M	-$40.42M	-$44.60M	-$57.44M
Net Income	-$65.95M	-$40.42M	-$44.60M	-$57.44M
Diluted EPS	-5.86	-3.57	-2.17	-1.34
Diluted Shares	11.26M	11.33M	20.59M	42.84M

TARA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$24.13M	$39.59M	$162.80M	$49.66M
Receivables	$486.00K	$242.00K	$0.00	$1.26M
Current Assets	$86.15M	$68.70M	$172.16M	$159.50M
Total Assets	$113.29M	$78.95M	$181.45M	$209.47M
Current Liabilities	$5.74M	$6.15M	$10.96M	$10.94M
Total Debt	$6.38M	$5.47M	$4.48M	$3.36M
Total Liabilities	$11.21M	$10.63M	$14.32M	$13.06M
Retained Earnings	-$159.96M	-$200.38M	-$244.98M	-$302.42M
Shareholders' Equity	$102.08M	$68.32M	$167.13M	$196.41M
Working Capital	$80.41M	$62.56M	$161.19M	$148.56M

TARA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$26.46M	-$37.56M	-$35.81M	-$56.37M
Capital Expenditure	-$120.00K	-$45.00K	-$63.00K	-$94.00K
Free Cash Flow	-$26.58M	-$37.60M	-$35.87M	-$56.46M
Depreciation & Amortisation	$248.00K	$341.00K	$332.00K	$362.00K
Stock-Based Compensation	$6.69M	$6.09M	$4.13M	$3.83M
Investing Cash Flow	$14.95M	$53.11M	$19.16M	-$139.49M
Financing Cash Flow	-$90.00K	-$91.00K	$139.87M	$82.72M
Share Repurchases	-$90.00K	-$91.00K	—	—
Net Change in Cash	-$11.60M	$15.46M	$123.21M	-$113.14M

TARA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$9.15M	$10.77M	$9.59M	$13.12M	$13.56M
Selling, General & Admin	$4.98M	$5.82M	$5.17M	$5.96M	$6.07M
Operating Expenses	$14.12M	$16.59M	$14.76M	$19.08M	$19.63M
Operating Income	-$14.12M	-$16.59M	-$14.76M	-$19.08M	-$19.63M
EBITDA	-$14.04M	-$16.49M	-$14.67M	-$18.99M	-$19.54M
Pretax Income	-$11.91M	-$14.96M	-$13.26M	-$17.31M	-$17.78M
Net Income	-$11.91M	-$14.96M	-$13.26M	-$17.31M	-$17.78M
Diluted EPS	-0.29	-0.35	-0.31	-0.37	-0.31
Diluted Shares	40.71M	42.27M	42.27M	46.04M	57.54M

TARA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$91.46M	$31.50M	$12.55M	$49.66M	$14.74M
Receivables	$368.00K	$890.00K	$1.00M	$1.26M	$1.52M
Current Assets	$126.53M	$125.09M	$135.64M	$159.50M	$140.00M
Total Assets	$168.56M	$156.93M	$144.64M	$209.47M	$191.92M
Current Liabilities	$7.02M	$9.76M	$9.91M	$10.94M	$8.92M
Total Debt	$4.23M	$3.95M	$3.66M	$3.36M	$3.06M
Total Liabilities	$10.07M	$12.51M	$12.35M	$13.06M	$10.71M
Retained Earnings	-$256.89M	-$271.85M	-$285.11M	-$302.42M	-$320.20M
Shareholders' Equity	$158.48M	$144.42M	$132.29M	$196.41M	$181.21M
Working Capital	$119.51M	$115.33M	$125.73M	$148.56M	$131.07M

TARA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$14.71M	-$12.25M	-$12.45M	-$16.95M	-$21.34M
Capital Expenditure	-$44.00K	-$22.00K	-$4.00K	-$24.00K	—
Free Cash Flow	-$14.76M	-$12.27M	-$12.46M	-$16.97M	-$21.34M
Depreciation & Amortisation	$83.00K	$98.00K	$88.00K	$93.00K	$90.00K
Stock-Based Compensation	$833.00K	$903.00K	$1.05M	$1.04M	$1.36M
Investing Cash Flow	-$58.35M	-$47.72M	-$6.51M	-$26.91M	-$14.72M
Financing Cash Flow	$1.73M	$8.00K	$13.00K	$80.96M	$1.14M
Net Change in Cash	-$71.34M	-$59.97M	-$18.95M	$37.11M	-$34.92M

Market Snapshot

About

Protara Therapeutics is a clinical-stage biopharmaceutical company developing transformative therapies for people with cancer and rare diseases. The company focuses on IV Choline Chloride for intestinal failure associated liver disease and TARA-002 for lymphatic malformations. Protara is advancing precision medicine approaches for underserved patient populations.